Predictive effect of combined evaluation of XRCC1, XPD and GSTP1 single nucleotide polymorphisms in platinum based chemotherapy
10.3760/cma.j.issn.1008-1372.2011.09.006
- VernacularTitle:联合分析XRCC1、XPD和GSTP1基因单核苷酸多态性在铂类药物化疗敏感性中的预测作用
- Author:
Yixin CHEN
;
Xianming LI
;
Hua BAI
;
Weixi SHEN
;
Feiqiu WEN
- Publication Type:Journal Article
- Keywords:
DNA-binding proteins/GE;
Xeroderma pigmentosum group D protein/GE;
Glutathione transferase/GE;
Organoplatinum compounds/AE;
Drug screening assays,antitumor
- From:
Journal of Chinese Physician
2011;13(9):1173-1176
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the predictive value of combined analysis on single nucleotide polymorphisms (SNPs) of X-ray cross-complementing1 ( XRCC1 ) gene 194 and 399 codon,xeroderma pigmentosum group D (XPD) gene 312 codon and glutathione S-transferase P1 (GSTP1) gene 105 codon in platinum based chemotherapy.Methods Direct sequencing was performed to detect XRCC1,XPD and GSTP1 genotypes in peripheral blood from 50 cancer patients receiving platinum-based chemotherapy.Genetic polymorphisms of these genes related to sensitivity of platinum were reviewed.Results Favorable genotypes were Arg/Trp and Trp/Trp in XRCC1 194 codon,Arg/Arg in XRCC1 399 codon,Asn/Asn in XPD 312 codon and Val/Val in GSTP1 105 codon.The response rate to chemotherapy was 57.1％,75.0％,60.9％,85.7％ and 87.5％,respectively.The response rate for patients possessing ≥2 favorable genotypes and those possessing 1 or 0 favorable genotype was 78.9％,36.4％ and 0,respectively.Patients possessing ≥2 favorable genotypes demonstrated higher sensitivity to platinum based chemotherapy,compared with those possessing 1 or 0 favorable genotype ( x2 =25.79,P ＜ 0.01 ).Conclusions Combination analysis of genomic polymorphisms of XRCC1,XPD and GSTP1 may be useful in predicting sensitivity of platinum based chemotherapy.
